Characteristics of undertreatment in COPD in the general population

Chest

Volumn 144, Issue 6, 2013, Pages 1811-1818

  Ingebrigtsen, Truls S ^a,b   Marott, Jacob L ^b   Vestbo, Jrøgen ^a,f   Hallas, Jesper ^a   Nordestgaard, Børge G ^c   Dahl, Morten ^d   Lange, Peter ^b,d,e  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING DRUG; SHORT ACTING DRUG;

ABSENTEEISM; ADULT; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONSULTATION; DISEASE EXACERBATION; DRUG UNDERTREATMENT; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GENDER; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RESPIRATORY TRACT INFECTION; SMOKING; TREATMENT OUTCOME; WIDOW; WIDOWER;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; BRONCHODILATOR AGENTS; COHORT STUDIES; DENMARK; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84890290435     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0453     Document Type: Article

References (33)

1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J. 2006;27(2):397-412.
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364(9434):613-620.
3. Vestbo J. Socioeconomic burden of chronic obstructive pulmonary disease. Eur Respir Monogr. 2006;11(38):463-469.
4. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143(5):317-326.
5. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
6. Vogelmeier C, Hederer B, Glaab T, et al POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103.
7. Tashkin DP, Celli B, Senn S, et al UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
8. Sandelowsky H, Ställberg B, Nager A, Hasselström J. The prevalence of undiagnosed chronic obstructive pulmonary disease in a primary care population with respiratory tract infections - a case finding study. BMC Fam Pract. 2011;12:122.
9. Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010;182(7):673-678.
10. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831-838.
11. Han MK. Medication adherence in COPD: what have we learned? Thorax. 2009;64(11):922-923.
12. Blais L, Bourbeau J, Sheehy O, LeLorier J. Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment. Can Respir J. 2004;11(1):27-32.
13. Cecere LM, Slatore CG, Uman JE, et al. Adherence to longacting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). COPD. 2012;9(3):251-258.
14. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309(22):2353-2361.
15. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: A study of the general population. Am J Respir Crit Care Med. 2012;186(10):975- 981.
16. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-365.
17. The Danish National Patient Registry. Statens Serum Institut website. http://www.ssi.dk/Sundhedsdataogit/Registre/Landspatientregisteret.aspx. Accessed June 5, 2013.
18. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445-448.
19. Norwegian Institute of Public Health, Oslo, Norway. ATC/DDD index 2013. WHO Collaborating Centre for Drug Statistics Methodology website. http://www.whocc.no/atc-ddd-index/. Accessed June 5, 2013.
20. Crawley MJ. The R Book. Chichester, England: John Wiley & Sons, Ltd; 2007.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley; 2000.
22. The Comprehensive R Archive Network. http://cran.r-project.org/. Accessed June 5, 2013.
23. Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis. 2012;7:1-9.
24. Lange P, Marott JL, Dahl M, Ingebrigtsen TS, Vestbo J, Nordestgaard BG. Substantial need for early diagnosis, rehabilitation and treatment of chronic obstructive pulmonary disease. Dan Med J. 2012;59(4):A4396.
25. Haupt D, Krigsman K, Nilsson JL. Medication persistence among patients with asthma/COPD drugs. Pharm World Sci. 2008;30(5):509-514.
26. Simoni-Wastila L, Wei YJ, Qian J, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am J Geriatr Pharmacother. 2012;10(3):201-210.
27. Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:493-501.
28. Yang Y, Thumula V, Pace PF, Banahan BF III, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009;31(10):2178-2188.
29. Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc. 2008;5(8):857-864.
30. Touchette DR, Shapiro NL. Medication compliance, adherence, and persistence: current status of behavioral and educational inverventions to improve outcomes. J Manag Care Pharm. 2008;14(16)(suppl S-d):S2-S10.
31. Sundhedsstyrelsen website. http://laegemiddelstyrelsen.dk/da/topics/ statistik,-priser-og-tilskud/tilskud-til-medicin/tilskudsgraenser.aspx. Accessed June 5, 2013.
32. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(3):371-384.
33. Laforest L, Denis F, Van Ganse E, et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J. 2010;19(2):148-154.